ArticleScientific reports2021
Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Breast cancer radiotherapy in patients with autoimmune or cancer-associated myositis: balancing oncological benefit and immune-mediated risk.Radiation oncology (London, England) · 2026Review
- Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data.RMD open · 2026Article
- Malignant erythema as a high-specificity cutaneous indicator of malignancy in adult dermatomyositis: a retrospective cohort study.Frontiers in immunology · 2026Article
- Clinical Characteristics and Malignancy Prevalence in Idiopathic Inflammatory Myopathies: A Single-Center Study from Southwestern Saudi Arabia.Open access rheumatology : research and reviews · 2026Article
- Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.Journal of clinical medicine · 2025Review
- Malignancy in Idiopathic Inflammatory Myopathies: Recent Insights.Clinical reviews in allergy & immunology · 2025Review
- A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade.BMC rheumatology · 2025Article
- Association of clinical features and myositis-specific antibodies in idiopathic inflammatory myopathy: a retrospective study from southern China.Frontiers in immunology · 2025Article
- Cancer in connective tissue disease.Frontiers in immunology · 2025Review
- Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.Frontiers in oncology · 2025Review
- Cancer and pulmonary fibrosis risks in patients with dermatomyositis and polymyositis: A retrospective cohort study.Heliyon · 2024Article
- The spectrum of idiopathic inflammatory myopathies in Western Australia: epidemiological characteristics and mortality over time.Rheumatology international · 2024Article
- Clinically amyopathic dermatomyositis associated with cutaneous ulcerations: a case-based review.Annals of medicine and surgery (2012) · 2024Article
- Explore the shared molecular mechanism between dermatomyositis and nasopharyngeal cancer by bioinformatic analysis.PloS one · 2024Article
- Two cases of dermatomyositis associated with neuroendocrine tumors.International cancer conference journal · 2024Article
- Research progress on the dermatomyositis specific autoantibodies and malignancy associated dermatomyositis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Paraneoplastic dermatomyositis associated with vocal cord carcinoma.BMJ case reports · 2023Article
- Paraneoplastic Neurologic Disorders.Current neurology and neuroscience reports · 2023Review
- Dermatomyositis with intrahepatic cholangiocarcinoma: a case report and data mining based on machine learning.Frontiers in oncology · 2023Article
- Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.Clinical reviews in allergy & immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study aimed to investigate the incidence, risk factors and time to occurrence of malignancy in patients with dermatomyositis (DM) and polymyositis (PM). The electronic medical records of 1100 patients with DM and 1164 patients with PM were studied between January 2001 and May 2019. Malignancies after myositis were diagnosed in 61 (5.55%) patients with DM and 38 (3.26%) patients with PM. The cumulative incidence of malignancies in patients with DM were significantly higher than patients with PM (hazard ratio = 1.78, log-rank p = 0.004). Patients with DM had a greater risk of developing malignancy than those with PM at 40-59 years old (p = 0.01). Most malignancies occurred within 1 year after the initial diagnosis of DM (n = 35; 57.38%). Nasopharyngeal cancer (NPC) was the most common type of malignancy in patients with DM (22.95%), followed by lung, and breast cancers. In patients with PM, colorectal, lung and hepatic malignancies were the top three types of malignancy. The risk factors for malignancy included old age (≥ 45 years old) and low serum levels of creatine phosphokinase (CPK) for patients with DM and male sex and low serum levels of CPK for patients with PM. Low serum levels of CPK in patients with myositis with malignancy represented a low degree of muscle destruction/inflammation, which might be attributed to activation of the PD-L1 pathway by tumor cells, thus inducing T-cell dysfunction mediating immune responses in myofibers. A treatment and follow-up algorithm should explore the occurrence of malignancy in different tissues and organs and suggested annual follow-ups for at least 5.5 years to cover the 80% cumulative incidence of malignancy in patients with DM and PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.